Genotype — phenotype correlations in Polish patients with hypertrophic cardiomyopathy. Preliminary report

Author: Tadeusz Osadnik, Anna Frycz-Kurek, Mateusz Lejawa, Martyna Fronczek, Justyna Małyszek-Tumidajewicz, Wioletta Szczurek-Wasilewicz, Karolina Macioł-Skurk, Mariusz Gąsior, Bożena Szyguła-Jurkiewicz

Article type: Short communication

Received: January 24, 2022

Accepted: February 17, 2022

Early publication date: February 17, 2022
Genotype — phenotype correlations in Polish patients with hypertrophic cardiomyopathy. Preliminary report

Tadeusz Osadnik1, 2, Anna Frycz-Kurek3, Mateusz Lejawa4, Martyna Fronczek1, 4, Justyna Małyszek-Tumidajewicz5, Wioletta Szczurek-Wasilewicz3, Karolina Macioł-Skurk3, Mariusz Gąsior6, Bożena Szygula-Jurkiewicz6

1Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
22nd Department of Cardiology and Angiology, Silesian Center for Heart Diseases, Zabrze, Poland
33rd Department of Cardiology, Silesian Center for Heart Diseases, Zabrze, Poland
4Kardio-Med Silesia, Zabrze, Poland
5Department of Cardiac, Vascular and Endovascular Surgery and Transplantology in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases, Zabrze, Poland
63rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

Correspondence to:
Tadeusz Osadnik, MD, PhD,
Department of Pharmacology,
Faculty of Medical Sciences in Zabrze,
Medical University of Silesia in Katowice,
Jordana 38, 41–800 Zabrze,
phone: +48 32 272 26 83,
e-mail: tadeusz.osadnik@icloud.com

Conflict of interest: None declared

INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is commonly defined by the presence of increased left ventricular (LV) wall thickness which cannot be explained by abnormal loading conditions such as arterial hypertension and/or aortic valve stenosis. The prevalence of HCM is 1:500, which makes it one of the most common genetic cardiological diseases [1].
According to the literature data, the isolated form of HCM is most often caused by the occurrence of pathogenic variants in genes encoding sarcomere proteins. Until now around 1500 pathogenic variants in 11 genes encoding sarcomere proteins were identified [2]. In this report, we present the clinical characteristics and the results of genetic testing of HCM patients diagnosed and treated in the 3rd Department and Clinical Department of Cardiology, Silesian Centre for Heart Diseases.

METHODS

48 consecutive patients with HCM were recruited during their routine follow-up visit in the 3rd Department of Cardiology, Silesian Centre for Heart Diseases in Zabrze. Blood for biochemical analyses was collected after 8-10 hours of fasting, additionally, blood for genetic analyses was secured and stored in –80°C. The family history of each patient was collected in detail. Two patients were excluded because the diagnosis of HCM was negatively verified. HCM sudden cardiac death risk score (HCM SCD risk score) was calculated for all patients [1]. Information regarding genetic and bioinformatics analysis is presented in Supplementary material.

Statistical analyses

Fisher’s exact test was used for detection of differences between categorical variables, whilst the Kruskal-Wallis test was used for detection of differences between continuous variables. Dunn test was used as a post hoc test for the Kruskal-Wallis test. Two-sided p-value <0.05 was considered statistically significant for all comparisons, with the exceptions of post-hoc test were Bonferroni correction was used. Continuous variables were reported as medians and interquartile ranges, categorical variables were reported as counts and percentages. Statistical analyses were carried out in R software [3].

RESULTS AND DISCUSSION

We were able to identify the pathogenic/likely pathogenic variants associated with the occurrence of HCM in 15 (32.6%). We have also found 16 additional variants that were classified as VUS. Interestingly 7 (44%) of those variants were predicted to have a significant damaging effect on coded protein by both SIFT and PolyPhen-2 prediction algorithms (PolyPhen-2 score ≥0.74 and Sift score ≤0.04). There were no significant differences in clinical characteristics between groups. There was however a trend toward higher HCM SCD risk score in patients with pathogenic/likely pathogenic variant (Table 1).
HCM is one of the most common cardiomyopathies. Despite this, only in 40%–60% of patients it is possible to identify the variant responsible for the disease [1]. The reason why it is not possible to identify causative variants in a large proportion of patients may due to involvement of other genes not yet identified to be associated with HCM. Oligo- or even polygenic inheritance may be another cause. In rare cases, copy number variations, microdeletions as well as incorrect classification of myocardial hypertrophy as HCM may be the reason [4, 5].

The most common pathogenic/likely pathogenic variants responsible for the occurrence of HCM in our population were identified in genes encoding proteins of the sarcomere, in particular *MYBPC3* and *MYH7*. This is consistent with the results of genetic testing of HCM patients from other populations [2, 4]. Our data suggested a possible relationship between higher risk of SCD assessed using the HCM SCD risk score [1, 6], in patients with confirmed pathogenic variant. This may reflect observations from other cohorts, that in patients with identified causative variant the disease tends to have more aggressive course [5]. The frequency of alcohol ablation or surgical myectomy was similar in both groups. Similar results were reported by et Loar et al. [5]. In general genotype-phenotype correlations in patients with HCM are modest [7,8]. Interestingly in one case, we found a variant in *RYR2* gene pathogenic for catecholaminergic ventricular tachycardia (CPVT) and not HCM. We did not find any other variants in this patient in genes typically associated with HCM. This patient was burdened with recurrent ventricular arrhythmias and his HCM-SCD risk score was calculated to be 24.7. In literature, *RYR2* variants were reported as a possible rare cause of HCM [9,10]. Association of pathogenic variant in this gene was also proved to be associated with HCM phenotype in animal studies [11]. Nonetheless, this variant will be subjected to segregation analysis and we will try to carry out whole-exome sequencing in this patient.

**CONCLUSIONS.**

In the studied population, we identified variants that might be responsible for the phenotype in 33% of patients. Further analysis is required to assess eventual pathogenicity of identified VUS found in 35% of cases.

**Article information**

Acknowledgments: This work was supported by a grant (KNW-1-124/N/8/0) from the Medical University of Silesia.
Ethical approval: The study was approved by the Bioethical Committee of the Medical University of Silesia (KNW/0022/KB1/102/18) and by the Bioethical Committee of the Chamber of Physicians (KBCz-0018/2015). The study was conducted according to the guidelines of the Declaration of Helsinki.

Supplementary material

Supplementary material is available at https://journals.viamedica.pl/kardiologia_polska.

REFERENCES


Table 1. Clinical characteristics of the study population, and variants identified as disease-causing in the studied population

<table>
<thead>
<tr>
<th>Pathogenic/likely pathogenic variant positive n = 15</th>
<th>Variant of uncertain significance n = 16</th>
<th>No identified pathogenic/VUS variant n = 15</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, median (IQR)</td>
<td>51 (37–59)</td>
<td>58 (46–68)</td>
<td>55 (40–65)</td>
</tr>
<tr>
<td>Male gender, n (%)</td>
<td>9 (60)</td>
<td>8 (50)</td>
<td>9 (60)</td>
</tr>
<tr>
<td>Heart Failure, n (%)</td>
<td>9 (60)</td>
<td>9 (56)</td>
<td>7 (47)</td>
</tr>
<tr>
<td>Alcohol ablation or myectomy of IVS, n (%)</td>
<td>1 (7)</td>
<td>3 (19)</td>
<td>2 (13)</td>
</tr>
<tr>
<td>Implantable cardioverter defibrillation, n (%)</td>
<td>6 (40)</td>
<td>5 (33)</td>
<td>5 (33)</td>
</tr>
<tr>
<td>Atrial fibrillation, n (%)</td>
<td>6 (40)</td>
<td>6 (38)</td>
<td>2 (13)</td>
</tr>
<tr>
<td>Ventricular tachycardia, n (%)</td>
<td>7 (47)</td>
<td>5 (31)</td>
<td>4 (27)</td>
</tr>
<tr>
<td>HCM-SCD risk score, median (IQR)</td>
<td>5.7 (4.5–9.4)</td>
<td>3.4 (2.1–7.1)</td>
<td>3.7 (2.3–5.4)</td>
</tr>
<tr>
<td>NT-proBNP, pg/ml, median (IQR)</td>
<td>906 (177–1651)</td>
<td>657 (404–1025)</td>
<td>349 (139–959)</td>
</tr>
<tr>
<td>Max. thickness of LV, mm, median (IQR)</td>
<td>20 (17.5–21)</td>
<td>19.5 (16–21.3)</td>
<td>18.0 (15.5–21)</td>
</tr>
</tbody>
</table>
LVOT Vmax (Valsalva), mm Hg, median (IQR)

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>Gene name</th>
<th>Identified variants</th>
</tr>
</thead>
<tbody>
<tr>
<td>MYBPC3</td>
<td>Myosin-binding protein C</td>
<td>Transcript: NM_000256.3, c.3490+1G&gt;T (2), c.3697C&gt;T, c.821+1G&gt;A, c.3040delC, c.3407_3409delACT, c.2449C&gt;T (2×)</td>
</tr>
<tr>
<td>MYH7</td>
<td>Myosin 7</td>
<td>Transcript: NM_000257.3, c.2555T&gt;C, c.5135G&gt;A, c.2011C&gt;T</td>
</tr>
<tr>
<td>MYL3</td>
<td>Essential myosin light chain 3</td>
<td>Transcript: NM_000258.2, c.170C&gt;G</td>
</tr>
<tr>
<td>TNNI3</td>
<td>Troponin I3</td>
<td>Transcript: NM_000363.5, c.407G&gt;A</td>
</tr>
<tr>
<td>TNNT2</td>
<td>Troponin T</td>
<td>Transcript: NM_000364.3, c.311G&gt;T</td>
</tr>
<tr>
<td>RYR2</td>
<td>Ryanodine receptor</td>
<td>Transcript: NM_001035.2, c.1069G&gt;A</td>
</tr>
</tbody>
</table>

*Reported as pathogenic and/or likely pathogenic by multiple sources; 1Reported as pathogenic and/or likely pathogenic and as VUS with in-silico analyses predicting damaging effect and/or functional studies; 2Variant pathogenic for CPVT, we cannot exclude that this is not a causative variant of HCM. Dichotomous variables are presented as counts and percentages. Values are presented as median and interquartile range (IQR)

Abbreviations: HCM, hypertrophic cardiomyopathy; IVS, interventricular septum; LVOT, left ventricular outflow tract; LVOTO, left ventricular outflow tract obstruction